Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6893080 | 0.86 | MMP8 (0.37) | MMP8CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL18558835 | 0.83 | MMP8 (0.35) | MMP8CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL20697581 | 0.81 | MMP8 (0.36) | MMP8 | |
| SCHEMBL18856319 | 0.81 | MMP8 (0.33) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL6899684 | 0.79 | MMP8 (0.39) | MMP8CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL22844468 | 0.77 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL19851975 | 0.74 | CYP4F2 (0.36) | MMP8CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL6895578 | 0.73 | CYP4F2 (0.40) | MMP8CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL18924778 | 0.73 | MMP8 (0.35) | MMP8CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL2982491 | 0.72 | MAPT (0.33) | MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428058-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-10-01 | — | — | US | disclosed |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-19 | — | — | US | disclosed |
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | MMP8 1033/4885CYP4F2 2245/4885CYP4A11 1511/4885 |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | MMP8 1033/4885CYP4F2 2245/4885CYP4A11 1511/4885 |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | MMP8 1033/4885CYP4F2 2245/4885CYP4A11 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.